KEY FINDINGS
The North America neurovascular devices / interventional neurology market growth is predicted to progress at a CAGR of 5.26% during the forecast period, 2021-2028. The rising prevalence of neurovascular disorders fuels market growth. The treatment for these disorders requires neurovascular devices.
MARKET INSIGHTS
Canada and the United States are assessed for the North America neurovascular devices / interventional neurology market growth evaluation. Stroke is the third leading cause of death in Canada. It is also a significant contributor to disability incidences. Also, there is a rise in neurological disorders across the country. As a result, the government is aiding research and development activities. The government is also providing funds for research in the brain health sector. For example, it announced funding of US$ 900 million in September 2016 for 13 universities through the CFREF (Canada First Research Excellence Fund).
Moreover, government organizations are offering aid to neurological condition patients. For example, the Neurological Health Charities Canada (NHCC) looks after people with brain injuries, disorders, and diseases. Furthermore, the secondary factors attributed to market growth include the rising demand for minimally invasive surgical procedures and favorable medical reimbursements.
COMPETITIVE INSIGHTS
Some of the prominent market players include Rapid Medical, Sensome, Stryker Corporation, Penumbra Inc, Phenox GmbH, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCIDENCE OF NEUROVASCULAR CONDITIONS
3.1.2. DEMAND FOR MINIMALLY INVASIVE PROCEDURES
3.1.3. SIGNIFICANCE OF NEUROLOGICAL DISEASES IN GERIATRIC POPULATION
3.1.4. PREVALENCE OF UNDERLYING DISEASE CONDITIONS
3.2. KEY RESTRAINTS
3.2.1. EXORBITANT COST OF NEUROVASCULAR DEVICES
3.2.2. LACK OF ADEQUATE NUMBER OF TRAINED NEUROSURGEONS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON NEUROVASCULAR DEVICES MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
5. MARKET BY PRODUCT
5.1. EMBOLIZATION DEVICES
5.2. ACCESSORY DEVICES
5.3. REVASCULARIZATION DEVICES
5.4. THROMBECTOMY DEVICES
5.5. EMBOLIC PROTECTION DEVICES
6. MARKET BY APPLICATION
6.1. ANEURYSM
6.2. ISCHEMIC STROKE
6.3. STENOSIS
6.4. ARTERIOVENOUS MALFORMATION (AVM)
6.5. OTHER APPLICATIONS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. MARKET SIZE & ESTIMATES
7.1.2. KEY GROWTH ENABLERS
7.1.3. KEY CHALLENGES
7.1.4. KEY PLAYERS
7.1.5. COUNTRY ANALYSIS
7.1.5.1. UNITED STATES
7.1.5.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS & DIVESTITURES
8.2. COMPANY PROFILES
8.2.1. ACANDIS GMBH
8.2.2. ASAHI INTECC
8.2.3. BALT USA LLC
8.2.4. B BRAUN MELSUNGEN AG
8.2.5. INTEGER HOLDINGS CORPORATION
8.2.6. JOHNSON & JOHNSON (CERENOVUS)
8.2.7. KANEKA CORPORATION
8.2.8. MEDTRONIC INC
8.2.9. MEMRY CORPORATION
8.2.10. MICROPORT SCIENTIFIC CORPORATION
8.2.11. PENUMBRA INC
8.2.12. PHENOX GMBH
8.2.13. RAPID MEDICAL
8.2.14. SENSOME
8.2.15. STRYKER CORPORATION
8.2.16. TERUMO MEDICAL CORPORATION (MICROVENTION INC)
1. ACANDIS GMBH
2. ASAHI INTECC
3. BALT
4. B BRAUN MELSUNGEN AG
5. INTEGER HOLDINGS CORPORATION
6. JOHNSON & JOHNSON (CERENOVUS)
7. KANEKA CORPORATION
8. MEDTRONIC INC
9. MEMRY CORPORATION
10. MICROPORT SCIENTIFIC CORPORATION
11. PENUMBRA INC
12. PHENOX GMBH
13. RAPID MEDICAL
14. SENSOME
15. STRYKER CORPORATION
16. TERUMO MEDICAL CORPORATION (MICROVENTION INC)
